InMed Pharmaceuticals Appoints CBIZ as Auditor Following Marcum Acquisition, Addresses Previous Material Weakness

Reuters
2025/06/14
InMed Pharmaceuticals Appoints CBIZ as Auditor Following Marcum Acquisition, Addresses Previous Material Weakness

InMed Pharmaceuticals Inc. recently announced a change in its auditor due to the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. Marcum resigned as InMed's auditor, effective June 12, 2025, and CBIZ has been appointed as the new auditor for the fiscal year ending June 30, 2025. The resignation was not related to any disagreements or reportable events concerning InMed's financial statements, which did not contain any adverse opinions or disclaimers. However, a previously disclosed material weakness related to the adequacy of resources for responding to financial reporting matters was noted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 255571) on June 13, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10